Prishniparni (Uraria picta)

Prishniparni (Uraria picta) is an Ayurvedic herb containing bioactive flavonoids and alkaloids, including psoralen and isoflavones, that drive its antioxidant and antihypertensive properties. Its primary mechanisms involve free radical scavenging via superoxide dismutase and catalase upregulation, alongside angiotensin-converting enzyme (ACE) inhibition to reduce blood pressure.

Origin & History

Prishniparni (Uraria picta) is a perennial undershrub from the Fabaceae family native to tropical regions of India, Southeast Asia, and parts of Africa. The plant is harvested from wild or cultivated sources for its roots and aerial parts, which are used medicinally in traditional preparations. All plant parts including roots, leaves, stems, and seeds contain bioactive compounds extracted using solvents like methanol for analysis.

Historical & Cultural Context

Prishniparni has been used in Ayurveda for over 2,000 years as part of Dashamoola (ten-root group) for balancing Vata, Pitta, and Kapha doshas. Traditional applications include treating fever, inflammation, diarrhea, bone fractures, cough, and toxin expulsion, with the herb classified as having bitter-sweet taste, hot potency, and supporting reproductive tissue and wound healing.

Health Benefits

• Antioxidant activity: Demonstrated 65% DPPH radical scavenging at 100 µg/mL in vitro studies, with extracts enhancing SOD and CAT enzymes (preliminary evidence)
• Antihypertensive effects: Animal studies showed 400 mg/kg body weight significantly reduced blood pressure and ACE activity (preliminary evidence)
• Antimicrobial properties: Root extracts showed activity against bacteria and fungi with MIC 12.5-200 µg/ml in vitro (preliminary evidence)
• Anti-inflammatory potential: Flavonoids and triterpenoid acids inhibit COX pathways and reduce pro-inflammatory cytokines IL-1β, IL-6, TNF-α (preliminary evidence)
• Cognitive support: Acetylcholinesterase and butyrylcholinesterase inhibition demonstrated dose-dependently in vitro (preliminary evidence)

How It Works

Uraria picta extracts scavenge free radicals via direct DPPH neutralization and upregulate endogenous antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT), reducing oxidative cellular damage. Its isoflavone and flavonoid constituents inhibit angiotensin-converting enzyme (ACE) activity, reducing the conversion of angiotensin I to the vasoconstrictive angiotensin II, thereby lowering peripheral vascular resistance. Psoralen and related coumarins may additionally modulate inflammatory cascades by suppressing COX-2 and NF-κB signaling pathways, though this mechanism requires further human validation.

Scientific Research

Currently, no human clinical trials, RCTs, or meta-analyses have been conducted on Prishniparni. All available evidence comes from preclinical in vitro and animal studies, including research showing 400 mg/kg body weight extracts significantly altered antioxidant enzymes and reduced blood pressure in animals. No PMIDs were provided in the research dossier.

Clinical Summary

In vitro studies demonstrate that Uraria picta extracts achieve 65% DPPH radical scavenging activity at 100 µg/mL, with concurrent enhancement of SOD and CAT enzyme levels, though these findings are limited to cell-based models. Animal studies using doses of 400 mg/kg body weight showed statistically significant reductions in systolic blood pressure and measurable decreases in ACE activity, supporting an antihypertensive mechanism. No randomized controlled human trials have been published to date, meaning all efficacy data derives from preliminary preclinical research. The overall evidence base is early-stage, and clinical extrapolation to human dosing and outcomes must be made with caution.

Nutritional Profile

Prishniparni (Uraria picta) is a medicinal herb rather than a dietary staple, so conventional macronutrient profiling is limited; available phytochemical and partial compositional data are as follows. Bioactive compounds (primary focus): Flavonoids including orientin, vitexin, and isovitexin identified in leaf and root extracts; total flavonoid content reported at approximately 12–18 mg quercetin equivalents/g dry extract in some studies. Alkaloids: piperidine-type alkaloids detected in root material at trace concentrations (<0.5% w/w). Terpenoids: lupeol and betulinic acid identified in root bark fractions. Glycosides: urariasaponins (triterpenoid saponins) reported in roots; total saponin content approximately 2–4% w/w dry root powder. Phenolic compounds: total phenolic content reported at approximately 45–60 mg gallic acid equivalents/g dry extract, contributing significantly to observed antioxidant activity. Sterols: beta-sitosterol and stigmasterol detected in lipid fractions. Crude fiber: estimated 8–14% w/w in dried aerial parts based on proximate analyses of related Fabaceae members. Crude protein: approximately 10–16% w/w in dried leaf material, typical for leguminous herbs. Minerals: calcium and iron present in aerial parts; specific concentrations not well-characterized in published literature, though Fabaceae herbs generally contain 200–400 mg calcium/100 g and 10–25 mg iron/100 g dry weight. Essential oils: trace volatile compounds including linalool and caryophyllene identified in leaf fractions. Bioavailability notes: Phenolic glycosides and saponins may have limited oral bioavailability due to poor gastrointestinal absorption; traditional preparations using water decoctions or milk-based formulations (as in Dashamula combinations) may enhance solubility of terpenoid fractions. Tannin content, if present, could reduce mineral bioavailability when consumed with food sources.

Preparation & Dosage

No clinically studied human dosages are available. Traditional Ayurvedic practice uses powders or decoctions of roots/aerial parts, but specific dosage ranges have not been quantified in research. Animal studies used 400 mg/kg body weight without reported toxicity. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Ashwagandha, Guduchi, Shatavari, Turmeric, Triphala

Safety & Interactions

Prishniparni has a long history of use in Ayurvedic formulations such as Dashamula, suggesting general tolerability at traditional doses, but rigorous human safety trials are absent. Its ACE-inhibitory activity poses a theoretical risk of additive hypotensive effects when combined with antihypertensive medications such as ACE inhibitors, ARBs, or beta-blockers, warranting medical supervision. The presence of psoralen, a furanocoumarin, raises potential photosensitivity concerns at high doses, and individuals on anticoagulant therapy should exercise caution due to possible coumarin-class interactions. Safety during pregnancy and lactation has not been established in clinical studies, and use during these periods is not recommended without physician guidance.